Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer



Page Path
HOME > J Liver Cancer > Volume 12(2); 2012 > Article
Review Article Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma
Myeong Jun Song
Journal of Liver Cancer 2012;12(2):88-92
Published online: September 30, 2012
  • 3 Download
  • 0 Crossref
  • 0 Scopus
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
Corresponding author:  Myeong Jun Song,

Transarterial chemoembolization (TACE) has been widely used as a standard treatment for HCC patients who are not suitable candidates for curative treatments and as a bridge to liver transplantation. The rationale for TACE is that the intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, will result in a strong cytotoxic effect combined with ischemia (conventional TACE). Recently, drug-eluting beads (DC Bead®) for the transcatheter treatment of HCC have been developed to deliver higher doses of chemotherapeutic agent and to prolong contact time with the tumor. DC Bead® has the ability to actively sequester doxorubicin hydrochloride from solution and release it in a controlled and sustained fashion. Treatment with DC Bead® has been shown to substantially diminish the amount of chemotherapeutic agent that reaches the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related adverse events. In this article, we describe the treatment efficacy and safety of TACE with the drug-eluting bead for the treatment of hepatocellular carcinoma and discuss future therapeutic possibilities.

JLC : Journal of Liver Cancer